These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 32540557)

  • 1. Immune checkpoint inhibition for non-small cell lung cancer in patients with pulmonary tuberculosis or Hepatitis B: Experience from a single Asian centre.
    Chan GH; Gwee YX; Low JL; Huang Y; Chan ZY; Choo JR; Ngoi NY; LE Ang Y; Muthu V; Chong WQ; Wong A; Soo RA
    Lung Cancer; 2020 Aug; 146():145-153. PubMed ID: 32540557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection.
    Pertejo-Fernandez A; Ricciuti B; Hammond SP; Marty FM; Recondo G; Rangachari D; Costa DB; Awad MM
    Lung Cancer; 2020 Jul; 145():181-185. PubMed ID: 32423643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence.
    Byeon S; Cho JH; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Cancer Med; 2020 Apr; 9(7):2352-2362. PubMed ID: 32027780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection.
    Shah NJ; Al-Shbool G; Blackburn M; Cook M; Belouali A; Liu SV; Madhavan S; He AR; Atkins MB; Gibney GT; Kim C
    J Immunother Cancer; 2019 Dec; 7(1):353. PubMed ID: 31847881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune-related hepatitis in non-small cell lung cancer patients with chronic hepatitis B.
    Hong J; Lee J; Park S; Jung HA; Sun JM; Lee SH; Ahn JS; Sinn DH; Ahn MJ
    Cancer; 2024 May; 130(9):1693-1701. PubMed ID: 38165808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
    Li X; Wang L; Chen S; Zhou F; Zhao J; Zhao W; Su C
    Thorac Cancer; 2020 Oct; 11(10):2812-2819. PubMed ID: 32779372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world efficacy and safety of immune checkpoint inhibitors in advanced hepatocellular carcinoma: Experience of a tertiary Asian Center.
    Ng KYY; Wong LWJ; Ang AJS; Tan SH; Choo SP; Tai DW; Lee JJX
    Asia Pac J Clin Oncol; 2021 Oct; 17(5):e249-e261. PubMed ID: 32875742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of tuberculosis in advanced lung cancer patients treated with immune checkpoint inhibitors - A nationwide population-based cohort study.
    Kim HW; Kim JS; Lee SH
    Lung Cancer; 2021 Aug; 158():107-114. PubMed ID: 34146757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer.
    Tone M; Izumo T; Awano N; Kuse N; Inomata M; Jo T; Yoshimura H; Minami J; Takada K; Miyamoto S; Kunitoh H
    Thorac Cancer; 2019 Oct; 10(10):2006-2012. PubMed ID: 31482678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitor plus chemotherapy as first-line treatment for non-small cell lung cancer with malignant pleural effusion: a retrospective multicenter study.
    Wei Q; Deng T; Wu J; Zeng H; Qi C; Tan S; Zhang Y; Huang Q; Pu X; Xu W; Li W; Tian P; Li Y
    BMC Cancer; 2024 Mar; 24(1):393. PubMed ID: 38549044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC.
    Schett A; Rothschild SI; Curioni-Fontecedro A; Krähenbühl S; Früh M; Schmid S; Driessen C; Joerger M
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):121-131. PubMed ID: 31745593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sarcopenia affects clinical efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients: A systematic review and meta-analysis.
    Wang J; Cao L; Xu S
    Int Immunopharmacol; 2020 Nov; 88():106907. PubMed ID: 33182031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors.
    Petrillo LA; El-Jawahri A; Nipp RD; Lichtenstein MRL; Durbin SM; Reynolds KL; Greer JA; Temel JS; Gainor JF
    Cancer; 2020 May; 126(10):2288-2295. PubMed ID: 32142165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study.
    Bjørnhart B; Hansen KH; Jørgensen TL; Herrstedt J; Schytte T
    Acta Oncol; 2019 Jul; 58(7):953-961. PubMed ID: 31081424
    [No Abstract]   [Full Text] [Related]  

  • 16. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
    Chu X; Zhao J; Zhou J; Zhou F; Jiang T; Jiang S; Sun X; You X; Wu F; Ren S; Zhou C; Su C
    Lung Cancer; 2020 Dec; 150():76-82. PubMed ID: 33080551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
    Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Relationship of Diabetes Mellitus to Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer.
    Jacobi O; Landman Y; Reinhorn D; Icht O; Sternschuss M; Rotem O; Finkel I; Allen AM; Dudnik E; Goldstein DA; Zer A
    Oncology; 2021; 99(9):555-561. PubMed ID: 34247166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
    Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of immune checkpoint inhibitor monotherapy for patients with massive non-small-cell lung cancer.
    Hakozaki T; Hosomi Y; Kitadai R; Kitagawa S; Okuma Y
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):2957-2966. PubMed ID: 32462297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.